Citadel Advisors
RCUS icon

Citadel Advisors’s Arcus Biosciences RCUS Stock Holding History

Citadel Advisors’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-10,000
Closed -$216K – 14648
2026
Q1 		$216K Sell
10,000
-27,300
-73% -$590K ﹤0.01% 11263
2025
Q4 		$889K Buy
37,300
+1,600
+4% +$32.6K ﹤0.01% 7644
2025
Q3 		$486K Sell
35,700
-4,600
-11% -$47.8K ﹤0.01% 9213
2025
Q2 		$328K Buy
40,300
+4,700
+13% +$40.1K ﹤0.01% 9595
2025
Q1 		$279K Buy
35,600
+13,000
+58% +$151K ﹤0.01% 9760
2024
Q4 		$337K Sell
22,600
-2,800
-11% -$45.7K ﹤0.01% 9420
2024
Q3 		$388K Sell
25,400
-3,700
-13% -$58.3K ﹤0.01% 8781
2024
Q2 		$443K Buy
29,100
+10,300
+55% +$166K ﹤0.01% 8301
2024
Q1 		$355K Sell
18,800
-14,300
-43% -$247K ﹤0.01% 9121
2023
Q4 		$632K Sell
33,100
-2,500
-7% -$40K ﹤0.01% 7608
2023
Q3 		$639K Sell
35,600
-4,100
-10% -$82.4K ﹤0.01% 7535
2023
Q2 		$806K Sell
39,700
-10,400
-21% -$198K ﹤0.01% 6908
2023
Q1 		$914K Sell
50,100
-16,500
-25% -$315K ﹤0.01% 6976
2022
Q4 		$1.38M Buy
66,600
+41,100
+161% +$1.13M ﹤0.01% 6205
2022
Q3 		$667K Sell
25,500
-73,400
-74% -$1.94M ﹤0.01% 7844
2022
Q2 		$2.51M Buy
98,900
+86,500
+698% +$2.12M ﹤0.01% 5101
2022
Q1 		$391K Sell
12,400
-27,000
-69% -$905K ﹤0.01% 9964
2021
Q4 		$1.59M Buy
39,400
+25,000
+174% +$970K ﹤0.01% 6743
2021
Q3 		$502K Sell
14,400
-32,500
-69% -$1.01M ﹤0.01% 9853
2021
Q2 		$1.29M Sell
46,900
-43,100
-48% -$1.23M ﹤0.01% 7685
2021
Q1 		$2.53M Buy
90,000
+3,200
+4% +$111K ﹤0.01% 5850
2020
Q4 		$2.25M Buy
86,800
+73,600
+558% +$1.78M ﹤0.01% 5106
2020
Q3 		$226K Buy
+13,200
New +$295K ﹤0.01% 8620

Other funds holding RCUS

GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Citadel Advisors's RCUS Position: Q2 2026 in Review

Citadel Advisors increased its Arcus Biosciences (RCUS) stake by 136% in Q2 2026, buying an estimated $44.6M and bringing the position to 3,135,057 shares worth $96.7M. The position accounts for 0.01% of the portfolio, ranked #994.

Citadel Advisors first reported a position in RCUS in Q1 2019 and has held it in 30 quarters since. 232 funds tracked by Wall St. Rank hold RCUS as of Q2 2026.

  • Citadel Advisors held 3,135,057 shares of Arcus Biosciences worth $96.7M as of Q2 2026.
  • Citadel Advisors bought 1,805,122 Arcus Biosciences shares in Q2 2026, an estimated $44.6M.
  • Arcus Biosciences made up 0.01% of Citadel Advisors's portfolio in Q2 2026, its #994 holding.
  • Citadel Advisors first reported a position in Arcus Biosciences in Q1 2019 and has held it in 30 quarters since.
  • 232 funds tracked by Wall St. Rank held Arcus Biosciences as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.